The vaccines were Pfizer, Moderna and AstraZeneca.
Vaccines cut the risk of severe COVID-19 by at least 90% in a huge real-world study of 23 million people
Dr. Catherine Schuster-Bruce Oct 12, 2021, 6:40 PM
- Vaccines cut the risk of developing severe COVID-19 by at least 90%, a study of 23 million people finds.
- COVID-19 vaccine protection lasted for at least five months in people aged 50 to 75, it found.
- It adds to a growing body of real-world evidence that vaccines hold up against severe COVID-19.
Vaccines cut the risk of severe COVID-19 by at least 90% in people who are 50 or older, a real-world study of nearly 23 million people has found.
The study, conducted by the French government-backed scientific organization Epi-Phare, found that five months after vaccination, people aged over 75 were 94% less likely to be hospitalized than unvaccinated people in the same age group.
The reduction in risk for those aged 50 to 74 was even higher, at 97%, the study authors said in a press release published Monday.
“This means that those who are vaccinated are nine times less at risk of being hospitalized or dying from COVID-19 than those who have not been vaccinated,” the epidemiologist Mahmoud Zureik, who oversaw the research, told Agence France-Presse, per The Guardian.
The study, which used data from the French National Health Data System, is one of the largest of its kind, comprising a total of 22.6 million people — 7.2 million over 75 years old and 15.4 million people aged 50 to 74.
It adds to a growing body of real-world research from the UK, US, and Israel that vaccines hold up against severe COVID-19 for at least five months.
For more: https://www.businessinsider.com/covid-vaccine-data-efficacy-effectiveness-severe-disease-french-study-data-2021-10?nr_email_referer=1&utm_source=Sailthru&utm_medium=email&utm_content=Insider%20Healthcare&utm_campaign=Post%20Blast%20healthcare:%20Inside%20a%20biotech%20VC%27s%20anger-driven%20strategy&utm_term=INSIDER%20HEALTHCARE%20-%20ENGAGED%2C%20ACTIVE%2C%20PASSIVE%2C%20DISENGAGED%2C%20NEW